

# Resource Summary Report

Generated by [kravitz2](#) on Aug 11, 2026

## XenoSTART

RRID:SCR\_026236

Type: Tool

---

### Proper Citation

XenoSTART (RRID:SCR\_026236)

---

### Resource Information

**URL:** <https://startresearch.com/preclinical/>

**Proper Citation:** XenoSTART (RRID:SCR\_026236)

**Description:** Oncology translational research organization focused on development and utilization of Patient-Derived Xenograft models. Preclinical contract research organization specializing in patient-derived xenografts.

**Resource Type:** commercial organization

**Keywords:** Oncology translational research organization, Patient-Derived Xenograft,

**Resource Name:** XenoSTART

**Resource ID:** SCR\_026236

**Record Creation Time:** 20250108T053322+0000

**Record Last Update:** 20260808T190740+0000

---

### Ratings and Alerts

No rating or validation information has been found for XenoSTART.

No alerts have been found for XenoSTART.

---

### Data and Source Information

**Source:** [SciCrunch Registry](#)

---

### Usage and Citation Metrics

We found 1 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [kravitz2](#) .

House NC, et al. (2025) CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen. NPJ breast cancer, 11(1), 135.